DOI: 10.12890/2026_007109

Effective treatment of audiovestibular involvement in Cogan’s syndrome with biologics and hyperbaric oxygen therapy

Authors

  • Angelika Biadacz-Sadurska Department of Internal Medicine and Rheumatology, Military Institute of Medicine – National Research Institute, Warsaw, Poland 0009-0007-9881-8028
  • Anna Krefta Department of Internal Medicine and Rheumatology, Military Institute of Medicine – National Research Institute, Warsaw, Poland
  • Witold Tłustochowicz Department of Internal Medicine and Rheumatology, Military Institute of Medicine – National Research Institute, Warsaw, Poland 0000-0001-7868-9272

angelika.biadacz97@gmail.com

Keywords

Cogan’s syndrome, hearing loss, infliximab, hyperbaric oxygen therapy (HBOT)

Abstract

Introduction: Cogan’s syndrome is a rare autoimmune disease typically affecting the ocular and audiovestibular system. Inner ear involvement is associated with a poor prognosis, as despite therapy, over 50% of patients develop profound deafness. The standard treatment remains the use of high dose glucocorticosteroids and immunosuppressants. Studies from recent years have reported significantly higher rates of improvement and recovery among patients treated with biologic disease modifying antirheumatic drugs (bDMARDs), particularly infliximab.
Case description: We report the case of a 39-year-old Caucasian female who experienced bilateral interstitial keratitis, sudden hearing loss, labyrinthine symptoms and arthralgia. Based on the clinical picture, Cogan’s syndrome was diagnosed. Initial treatment included high doses of glucocorticosteroids which did not result in a satisfactory clinical response. Due to the high risk of permanent deafness, it was decided to administer infliximab. Simultaneously, subcutaneous methotrexate was introduced, and the patient was referred for hyperbaric oxygen therapy. Follow-up hearing tests conducted four weeks later revealed a significant improvement. As a result of the treatment, hearing normalized and labyrinthine and ophthalmological as well as systemic symptoms disappeared.
Conclusion: Considering the unfavourable prognosis in Cogan’s syndrome with vestibulocochlear involvement, it seems reasonable to quickly escalate treatment if there is no sufficient response to glucocorticosteroids within two weeks. Infliximab has the most documented effectiveness among DMARDs. Combining pharmacotherapy with HBOT can significantly improves treatment outcomes.

View the entire article

Downloads

References

  1. Cundiff J, Kansal S, Kumar A, Goldstein DA, Tessler HH. Cogan’s syndrome: a cause of progressive hearing deafness. Am J Otolaryngol 2006;27:68-70. doi: 10.1016/j.amjoto.2005.07.006
  2. Bowers E, Tripathy K. Cogan Syndrome. StatPearls [Internet]. Treasure Island [FL]: StatPearls Publishing; 2026 Jan 10. Available from: https://www.ncbi.nlm.nih.gov/books/NBK580546/
  3. Arnaud L, Audemard-Verger A, Belot A, Bienvenu B, Burillon C, Chasset F, et al. French protocol for diagnosis and management of Cogan’s syndrome. Rev Med Interne 2025;46:74-88. doi: 10.1016/j.revmed.2024.09.007
  4. Haynes BF, Kaiser-Kupfer MI, Mason P, Fauci AS. Cogan syndrome: studies in thirteen patients, long-term follow-up, and a review of the literature. Medicine (Baltimore) 1980;59:426-441
  5. Padoan R, Cazzador D, Pendolino AL, Felicetti M, De Pascalis S, Zanoletti E, et al. Cogan’s syndrome: new therapeutic approaches in the biological era. Expert Opin Biol Ther 2019;19:781-788. doi: 10.1080/14712598.2019.1611779
  6. Beccastrini E, Emmi G, Squatrito D, Vannucchi P, Emmi L. Infliximab and Cogan’s syndrome. Clin Otolaryngol 2010;35: 441–442. doi: 10.1111/j.1749-4486.2010.02180.x
  7. Gluth MB, Baratz KH, Matteson EL, Driscoll CL. Cogan syndrome: a retrospective review of 60 patients throughout a half century. Mayo Clin Proc 2006;81:483-488. doi: 10.4065/81.4.483
  8. Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: An animal study followed by clinical application. Laryngoscope 1999;109:1–17. doi: 10.1097/00005537-199907001-00001
  9. Iliescu DA, Timaru CM, Batras M, De Simone A, Stefan C. COGAN’S SYNDROME. Rom J Opthalmol 2015;59:6-13.
  10. Marrero-Gonzalez AR, Ward C, Nguyen SA, Jeong SS, Rizk HG. Audiovestibular outcomes in adult patients with cogan syndrome: a systematic review. Eur Arch Otorhinolaryngol 2025;282:23-35. doi: 10.1007/s00405-024-08878-5
  11. Durtette C, Hachulla E, Resche-Rigon M, Papo T, Zénone T, Lioger B, et al. Cogan syndrome: Characteristics, outcome and treatment in a French nationwide retrospective study and literature review. Autoimmun Rev 2017;16:1219-1223. doi: 10.1016/j.autrev.2017.10.005
  12. Touma Z, Nawwar R, Hadi U, Hourani M, Arayssi T. The use of TNF-alpha blockers in Cogan’s syndrome. Rheumatol Int 2007;27:995–996. doi: 10.1007/s00296-007-0373-y
  13. Chandrasekhar SS, Tsai Do BS, Schwartz SR, Bontempo LJ, Faucett EA, Finestone SA, et al. Clinical Practice Guideline: Sudden Hearing Loss (Update). Otolaryngol Head Neck Surg 2019;161:S1-S45. doi: 10.1177/0194599819859885
  14. D’Aguanno V, Ralli M, de Vincentiis M, Greco A. Optimal management of Cogan’s syndrome: a multidisciplinary approach. J Multidiscip Healthc 2017;11:1-11. doi: 10.2147/JMDH.S150940

Published

2026-07-09

Issue

Vol. 13 No. 7 (2026)

Categories

How to Cite

1.
Biadacz-Sadurska A, Krefta A, Tłustochowicz W. Effective treatment of audiovestibular involvement in Cogan’s syndrome with biologics and hyperbaric oxygen therapy. EJCRIM [Internet]. 2026 Jul. 9 [cited 2026 Nov. 3];13(7). Available from: https://ejcrim.com/index.php/ejcrim/article/view/7109